Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Air-liquid interface (ALI) is an experimental cell culture configuration rather than a specific molecular target or receptor. In this system, epithelial cells are cultured on a porous membrane where the basal surface is submerged in nutrient media and the apical surface is exposed to the atmosphere, mimicking the physiological environment of the human respiratory tract [1]. This physical arrangement induces cells to undergo mucociliary differentiation, resulting in a pseudostratified epithelium containing specialized cell types such as ciliated cells, mucus-secreting goblet cells, and basal cells [2]. ALI models serve as a critical bridge between standard in vitro cell cultures and in vivo animal models, particularly for studying respiratory pathologies like asthma, COPD, and cystic fibrosis [3]. While ALI is a gold-standard platform for evaluating the transport, metabolism, and toxicity of inhaled drugs, it does not possess molecular classifications or drug-binding sites typical of therapeutic targets.
Not applicable; the air-liquid interface is a methodological setup for cell culture and not a protein, enzyme, or receptor target for drug binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Air-liquid interface (ALI).